|Bid||0.00 x 1000|
|Ask||0.00 x 900|
|Day's Range||36.69 - 37.00|
|52 Week Range||31.01 - 39.45|
|Beta (3Y Monthly)||1.18|
|PE Ratio (TTM)||96.93|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
QIAGEN N.V. plans as previously announced to release its report on results for the fourth quarter 2018 on Monday, February 4 at approximately 22:05 Central European Time / 16:05 Eastern Standard Time .
Fourth generation latent TB blood test provides flexible workflow and novel CD8 technology for a more complete picture of patients' immune response to tuberculosis infection
Adapting the power of QuantiFERON®-TB technology to advance global TB control efforts in new partnership with Ellume
Enhancing QIAGEN’s industry-leading position with access to MarkerMine™ database and real-world evidence insights that provide insights for targeted therapy options
Preparing for 2020 launch of novel digital PCR systems with fully integrated workflow and menu of QIAGEN assays, advantages of improved multiplexing, throughput and scalability
Enabling labs to efficiently process increasingly complex samples with over 3,000 proven protocols, advanced digital capabilities and connectivity
QIAGEN N.V. announces that it will initiate the repurchase of a third tranche of shares under the share repurchase program which was announced by an ad hoc announcement dated January 31, 2018. In the time period between December 19, 2018 until March 8, 2019, at the latest, a third tranche of up to 2.5 million common shares of the Company having a total purchase price of up to USD 70 million (or the equivalent Euro amount thereof, in each case without ancillary purchasing costs) shall be repurchased exclusively on the electronic trading platform of the Frankfurt Stock Exchange (XETRA). The maximum purchase price per share (excluding ancillary purchase costs) will not exceed the average closing price for the last five trading days prior to the day of purchase on the electronic trading platform of the Frankfurt Stock Exchange by more than 10%.
Fast-tracking clinical readiness of test to support identification of patients eligible for novel Novartis PI3K inhibitor BYL719
Partners discuss efforts to accelerate precision medicine solutions at ASH 2018 HILDEN, Germany and GERMANTOWN, Md. and FORT MYERS, Fla., Nov. 30, 2018 -- QIAGEN N.V. (NYSE:.
Partners discuss efforts to accelerate precision medicine solutions at ASH 2018
Highlighting Sample to Insight solutions for next-generation sequencing at American Society of Hematology 2018 meeting
NEW YORK, Nov. 13, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Sample to Insight solutions enabling deep analysis of disease-related genomic mutations
Adding QCI Analyze Universal to NGS bioinformatics offering, plus immuno-oncology content and additional features in analysis and interpretation
New gastrointestinal panel includes comprehensive viral coverage and provides Sample to Insight workflows to clinics in Europe and Australia
QIAGEN N.V. plans as previously announced to release its report on results for the third quarter 2018 on Monday, October 29 shortly after 21:00 Central European Time / 16:00 Eastern Daylight Time .
Studies on new QIAGEN solutions for NGS are presented at ASHG as QIAseq portfolio and user base expands significantly
Frankfurt Prime Standard: QIA) today applauded a commitment by world leaders attending the first-ever high-level United Nations meeting on tuberculosis (TB) to mobilize $13 billion a year by 2022 to implement prevention and care for TB, the world’s most deadly infectious disease. The heads of state meeting at the United Nations General Assembly pledged to ensure that 40 million people who are diagnosed with tuberculosis receive the care they need by the end of 2022 and agreed to provide preventive testing and treatment to 30 million people.
Approval allows use of therascreen® EGFR RGQ PCR Kit as a companion diagnostic for Pfizer’s VIZIMPRO® in patients with non-small cell lung cancer
CE-marked workflow enables efficient, high-throughput screening for tuberculosis control efforts in Europe and other markets; introduction in United States expected in 2019 and Chi
QIAGEN to launch two Sample to Insight systems in Europe and other markets, NeuMoDx to commercialize in the U.S. / Initial assay menu for infectious diseases and LDTs
Frankfurt Prime Standard: QIA) announced today that its global shares will be included in Germany’s MDAX index as of September 24, 2018, in addition to the current listing in the country’s TecDAX index. The addition to the MDAX – which will now track the next 60 largest companies on the German stock market after the 30 largest stocks in the DAX index – comes as part of a reorganization of index rules adopted by Deutsche Boerse, operator of the Frankfurt Stock Exchange.
NEW YORK, NY / ACCESSWIRE / August 1, 2018 / QIAGEN NV (NYSE: QGEN ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 1, 2018 at 9:00:00 AM Eastern Time. To listen ...
Day-one lab readiness speeds commercialization and reimbursement in personalized medicine